The global market for Erythropoietin Biosimilar was estimated to be worth US$ 1356 million in 2023 and is forecast to a readjusted size of US$ 2070.4 million by 2030 with a CAGR of 6.3% during the forecast period 2024-2030

Erythropoietin Biosimilar - Market

Erythropoietin (EPO) is the major glycoprotein hormone regulator of mammalian erythropoiesis , and is produced by kidney and liver in an oxygen-dependent manner. The biological effects of EPO are mediated by the specific erythropoietin receptor (EPOR) on bone marrow erythroblasts, which transmits signals important for both proliferation and differentiation along the erythroid lineage. EPOR is a type 1 single-transmembrane cytokine receptor, and belongs to the homodimerizing subclass which functions as ligand-induced or ligand-stabilized homodimers. EPOR pre-exists as dimers which upon binding of a 34 kDa ligand erythropoietin (Epo), changes its homodimerized state. These conformational changes result in the autophosphorylation of Jak2 kinases that are pre-associated with the receptor. Erythropoietin is necessary to maintain endothelial cells and to promote tumor angiogenesis, hence the dysregulation of EpoR may affect the growth of certain tumors. EpoR signaling prevents neuronal death and ischemic injury.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Erythropoietin Biosimilar, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Erythropoietin Biosimilar by region & country, by Type, and by Application.

The Erythropoietin Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Erythropoietin Biosimilar.

Market Segmentation

Scope of Erythropoietin Biosimilar - Market Report

Report Metric	Details
Report Name	Erythropoietin Biosimilar - Market
Forecasted market size in 2030	US$ 2070.4 million
CAGR	6.3%
Forecasted years	2024 - 2030
Segment by Type:	Hospital Pharmacy Retail Pharmacy Online Pharmacy
Segment by Application	Hematology Kidney Disorder Cancer Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, VHB Life Sciences, Chengdu Di'Ao Pharmaceutical Group, Chalver Laboratorios, Fresenius Kabi, Neiss Labs, Micro Labs, Zuventus Healthcare, RPG Life Sciences, Unilab, Incepta Pharmaceuticals, Genius Biotherapeutics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Erythropoietin Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Erythropoietin Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Erythropoietin Biosimilar in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Erythropoietin Biosimilar - Market size in 2030?

Ans: The Erythropoietin Biosimilar - Market size in 2030 will be US$ 2070.4 million.

Who are the main players in the Erythropoietin Biosimilar - Market report?

Ans: The main players in the Erythropoietin Biosimilar - Market are Pfizer, VHB Life Sciences, Chengdu Di'Ao Pharmaceutical Group, Chalver Laboratorios, Fresenius Kabi, Neiss Labs, Micro Labs, Zuventus Healthcare, RPG Life Sciences, Unilab, Incepta Pharmaceuticals, Genius Biotherapeutics

What are the Application segmentation covered in the Erythropoietin Biosimilar - Market report?

Ans: The Applications covered in the Erythropoietin Biosimilar - Market report are Hematology, Kidney Disorder, Cancer, Others

What are the Type segmentation covered in the Erythropoietin Biosimilar - Market report?

Ans: The Types covered in the Erythropoietin Biosimilar - Market report are Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

1 Market Overview

1.1 Erythropoietin Biosimilar Product Introduction

1.2 Global Erythropoietin Biosimilar Market Size Forecast

1.2.1 Global Erythropoietin Biosimilar Sales Value (2019-2030)

1.2.2 Global Erythropoietin Biosimilar Sales Volume (2019-2030)

1.2.3 Global Erythropoietin Biosimilar Sales Price (2019-2030)

1.3 Erythropoietin Biosimilar Market Trends & Drivers

1.3.1 Erythropoietin Biosimilar Industry Trends

1.3.2 Erythropoietin Biosimilar Market Drivers & Opportunity

1.3.3 Erythropoietin Biosimilar Market Challenges

1.3.4 Erythropoietin Biosimilar Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Erythropoietin Biosimilar Players Revenue Ranking (2023)

2.2 Global Erythropoietin Biosimilar Revenue by Company (2019-2024)

2.3 Global Erythropoietin Biosimilar Players Sales Volume Ranking (2023)

2.4 Global Erythropoietin Biosimilar Sales Volume by Company Players (2019-2024)

2.5 Global Erythropoietin Biosimilar Average Price by Company (2019-2024)

2.6 Key Manufacturers Erythropoietin Biosimilar Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Erythropoietin Biosimilar Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Erythropoietin Biosimilar

2.9 Erythropoietin Biosimilar Market Competitive Analysis

2.9.1 Erythropoietin Biosimilar Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Erythropoietin Biosimilar Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Erythropoietin Biosimilar as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Hospital Pharmacy

3.1.2 Retail Pharmacy

3.1.3 Online Pharmacy

3.2 Global Erythropoietin Biosimilar Sales Value by Type

3.2.1 Global Erythropoietin Biosimilar Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Erythropoietin Biosimilar Sales Value, by Type (2019-2030)

3.2.3 Global Erythropoietin Biosimilar Sales Value, by Type (%) (2019-2030)

3.3 Global Erythropoietin Biosimilar Sales Volume by Type

3.3.1 Global Erythropoietin Biosimilar Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Erythropoietin Biosimilar Sales Volume, by Type (2019-2030)

3.3.3 Global Erythropoietin Biosimilar Sales Volume, by Type (%) (2019-2030)

3.4 Global Erythropoietin Biosimilar Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hematology

4.1.2 Kidney Disorder

4.1.3 Cancer

4.1.4 Others

4.2 Global Erythropoietin Biosimilar Sales Value by Application

4.2.1 Global Erythropoietin Biosimilar Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Erythropoietin Biosimilar Sales Value, by Application (2019-2030)

4.2.3 Global Erythropoietin Biosimilar Sales Value, by Application (%) (2019-2030)

4.3 Global Erythropoietin Biosimilar Sales Volume by Application

4.3.1 Global Erythropoietin Biosimilar Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Erythropoietin Biosimilar Sales Volume, by Application (2019-2030)

4.3.3 Global Erythropoietin Biosimilar Sales Volume, by Application (%) (2019-2030)

4.4 Global Erythropoietin Biosimilar Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Erythropoietin Biosimilar Sales Value by Region

5.1.1 Global Erythropoietin Biosimilar Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Erythropoietin Biosimilar Sales Value by Region (2019-2024)

5.1.3 Global Erythropoietin Biosimilar Sales Value by Region (2025-2030)

5.1.4 Global Erythropoietin Biosimilar Sales Value by Region (%), (2019-2030)

5.2 Global Erythropoietin Biosimilar Sales Volume by Region

5.2.1 Global Erythropoietin Biosimilar Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Erythropoietin Biosimilar Sales Volume by Region (2019-2024)

5.2.3 Global Erythropoietin Biosimilar Sales Volume by Region (2025-2030)

5.2.4 Global Erythropoietin Biosimilar Sales Volume by Region (%), (2019-2030)

5.3 Global Erythropoietin Biosimilar Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Erythropoietin Biosimilar Sales Value, 2019-2030

5.4.2 North America Erythropoietin Biosimilar Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Erythropoietin Biosimilar Sales Value, 2019-2030

5.5.2 Europe Erythropoietin Biosimilar Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Erythropoietin Biosimilar Sales Value, 2019-2030

5.6.2 Asia Pacific Erythropoietin Biosimilar Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Erythropoietin Biosimilar Sales Value, 2019-2030

5.7.2 South America Erythropoietin Biosimilar Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Erythropoietin Biosimilar Sales Value, 2019-2030

5.8.2 Middle East & Africa Erythropoietin Biosimilar Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Erythropoietin Biosimilar Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Erythropoietin Biosimilar Sales Value

6.2.1 Key Countries/Regions Erythropoietin Biosimilar Sales Value, 2019-2030

6.2.2 Key Countries/Regions Erythropoietin Biosimilar Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Erythropoietin Biosimilar Sales Value, 2019-2030

6.3.2 United States Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Erythropoietin Biosimilar Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Erythropoietin Biosimilar Sales Value, 2019-2030

6.4.2 Europe Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Erythropoietin Biosimilar Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Erythropoietin Biosimilar Sales Value, 2019-2030

6.5.2 China Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

6.5.3 China Erythropoietin Biosimilar Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Erythropoietin Biosimilar Sales Value, 2019-2030

6.6.2 Japan Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Erythropoietin Biosimilar Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Erythropoietin Biosimilar Sales Value, 2019-2030

6.7.2 South Korea Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Erythropoietin Biosimilar Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Erythropoietin Biosimilar Sales Value, 2019-2030

6.8.2 Southeast Asia Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Erythropoietin Biosimilar Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Erythropoietin Biosimilar Sales Value, 2019-2030

6.9.2 India Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

6.9.3 India Erythropoietin Biosimilar Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Pfizer

7.1.1 Pfizer Company Information

7.1.2 Pfizer Introduction and Business Overview

7.1.3 Pfizer Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Pfizer Erythropoietin Biosimilar Product Offerings

7.1.5 Pfizer Recent Development

7.2 VHB Life Sciences

7.2.1 VHB Life Sciences Company Information

7.2.2 VHB Life Sciences Introduction and Business Overview

7.2.3 VHB Life Sciences Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.2.4 VHB Life Sciences Erythropoietin Biosimilar Product Offerings

7.2.5 VHB Life Sciences Recent Development

7.3 Chengdu Di'Ao Pharmaceutical Group

7.3.1 Chengdu Di'Ao Pharmaceutical Group Company Information

7.3.2 Chengdu Di'Ao Pharmaceutical Group Introduction and Business Overview

7.3.3 Chengdu Di'Ao Pharmaceutical Group Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Chengdu Di'Ao Pharmaceutical Group Erythropoietin Biosimilar Product Offerings

7.3.5 Chengdu Di'Ao Pharmaceutical Group Recent Development

7.4 Chalver Laboratorios

7.4.1 Chalver Laboratorios Company Information

7.4.2 Chalver Laboratorios Introduction and Business Overview

7.4.3 Chalver Laboratorios Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Chalver Laboratorios Erythropoietin Biosimilar Product Offerings

7.4.5 Chalver Laboratorios Recent Development

7.5 Fresenius Kabi

7.5.1 Fresenius Kabi Company Information

7.5.2 Fresenius Kabi Introduction and Business Overview

7.5.3 Fresenius Kabi Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Fresenius Kabi Erythropoietin Biosimilar Product Offerings

7.5.5 Fresenius Kabi Recent Development

7.6 Neiss Labs

7.6.1 Neiss Labs Company Information

7.6.2 Neiss Labs Introduction and Business Overview

7.6.3 Neiss Labs Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Neiss Labs Erythropoietin Biosimilar Product Offerings

7.6.5 Neiss Labs Recent Development

7.7 Micro Labs

7.7.1 Micro Labs Company Information

7.7.2 Micro Labs Introduction and Business Overview

7.7.3 Micro Labs Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Micro Labs Erythropoietin Biosimilar Product Offerings

7.7.5 Micro Labs Recent Development

7.8 Zuventus Healthcare

7.8.1 Zuventus Healthcare Company Information

7.8.2 Zuventus Healthcare Introduction and Business Overview

7.8.3 Zuventus Healthcare Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Zuventus Healthcare Erythropoietin Biosimilar Product Offerings

7.8.5 Zuventus Healthcare Recent Development

7.9 RPG Life Sciences

7.9.1 RPG Life Sciences Company Information

7.9.2 RPG Life Sciences Introduction and Business Overview

7.9.3 RPG Life Sciences Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.9.4 RPG Life Sciences Erythropoietin Biosimilar Product Offerings

7.9.5 RPG Life Sciences Recent Development

7.10 Unilab

7.10.1 Unilab Company Information

7.10.2 Unilab Introduction and Business Overview

7.10.3 Unilab Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.10.4 Unilab Erythropoietin Biosimilar Product Offerings

7.10.5 Unilab Recent Development

7.11 Incepta Pharmaceuticals

7.11.1 Incepta Pharmaceuticals Company Information

7.11.2 Incepta Pharmaceuticals Introduction and Business Overview

7.11.3 Incepta Pharmaceuticals Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.11.4 Incepta Pharmaceuticals Erythropoietin Biosimilar Product Offerings

7.11.5 Incepta Pharmaceuticals Recent Development

7.12 Genius Biotherapeutics

7.12.1 Genius Biotherapeutics Company Information

7.12.2 Genius Biotherapeutics Introduction and Business Overview

7.12.3 Genius Biotherapeutics Erythropoietin Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.12.4 Genius Biotherapeutics Erythropoietin Biosimilar Product Offerings

7.12.5 Genius Biotherapeutics Recent Development

8 Industry Chain Analysis

8.1 Erythropoietin Biosimilar Industrial Chain

8.2 Erythropoietin Biosimilar Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Erythropoietin Biosimilar Sales Model

8.5.2 Sales Channel

8.5.3 Erythropoietin Biosimilar Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Incepta Pharmaceuticals

Chengdu Di'Ao Pharmaceutical Group

Chalver Laboratorios

Genius Biotherapeutics

List of Tables

Table 1. Erythropoietin Biosimilar Market Trends

Table 2. Erythropoietin Biosimilar Market Drivers & Opportunity

Table 3. Erythropoietin Biosimilar Market Challenges

Table 4. Erythropoietin Biosimilar Market Restraints

Table 5. Global Erythropoietin Biosimilar Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Erythropoietin Biosimilar Revenue Market Share by Company (2019-2024)

Table 7. Global Erythropoietin Biosimilar Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Erythropoietin Biosimilar Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Erythropoietin Biosimilar Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Erythropoietin Biosimilar Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Erythropoietin Biosimilar Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Erythropoietin Biosimilar

Table 13. Global Erythropoietin Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Erythropoietin Biosimilar as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Erythropoietin Biosimilar Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Erythropoietin Biosimilar Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Erythropoietin Biosimilar Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Erythropoietin Biosimilar Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Erythropoietin Biosimilar Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Erythropoietin Biosimilar Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Erythropoietin Biosimilar Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Erythropoietin Biosimilar Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Erythropoietin Biosimilar Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Erythropoietin Biosimilar Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Erythropoietin Biosimilar Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Erythropoietin Biosimilar Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Erythropoietin Biosimilar Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Erythropoietin Biosimilar Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Erythropoietin Biosimilar Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Erythropoietin Biosimilar Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Erythropoietin Biosimilar Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Erythropoietin Biosimilar Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Erythropoietin Biosimilar Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Erythropoietin Biosimilar Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Erythropoietin Biosimilar Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Erythropoietin Biosimilar Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Erythropoietin Biosimilar Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Erythropoietin Biosimilar Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Erythropoietin Biosimilar Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Erythropoietin Biosimilar Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Erythropoietin Biosimilar Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Erythropoietin Biosimilar Sales Value by Region (2019-2024) & (%)

Table 44. Global Erythropoietin Biosimilar Sales Value by Region (2025-2030) & (%)

Table 45. Global Erythropoietin Biosimilar Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Erythropoietin Biosimilar Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Erythropoietin Biosimilar Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Erythropoietin Biosimilar Sales Volume by Region (2019-2024) & (%)

Table 49. Global Erythropoietin Biosimilar Sales Volume by Region (2025-2030) & (%)

Table 50. Global Erythropoietin Biosimilar Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Erythropoietin Biosimilar Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Erythropoietin Biosimilar Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Erythropoietin Biosimilar Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Erythropoietin Biosimilar Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Erythropoietin Biosimilar Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Erythropoietin Biosimilar Sales Volume, (2025-2030) & (K Units)

Table 57. Pfizer Company Information

Table 58. Pfizer Introduction and Business Overview

Table 59. Pfizer Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. Pfizer Erythropoietin Biosimilar Product Offerings

Table 61. Pfizer Recent Development

Table 62. VHB Life Sciences Company Information

Table 63. VHB Life Sciences Introduction and Business Overview

Table 64. VHB Life Sciences Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. VHB Life Sciences Erythropoietin Biosimilar Product Offerings

Table 66. VHB Life Sciences Recent Development

Table 67. Chengdu Di'Ao Pharmaceutical Group Company Information

Table 68. Chengdu Di'Ao Pharmaceutical Group Introduction and Business Overview

Table 69. Chengdu Di'Ao Pharmaceutical Group Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Chengdu Di'Ao Pharmaceutical Group Erythropoietin Biosimilar Product Offerings

Table 71. Chengdu Di'Ao Pharmaceutical Group Recent Development

Table 72. Chalver Laboratorios Company Information

Table 73. Chalver Laboratorios Introduction and Business Overview

Table 74. Chalver Laboratorios Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Chalver Laboratorios Erythropoietin Biosimilar Product Offerings

Table 76. Chalver Laboratorios Recent Development

Table 77. Fresenius Kabi Company Information

Table 78. Fresenius Kabi Introduction and Business Overview

Table 79. Fresenius Kabi Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Fresenius Kabi Erythropoietin Biosimilar Product Offerings

Table 81. Fresenius Kabi Recent Development

Table 82. Neiss Labs Company Information

Table 83. Neiss Labs Introduction and Business Overview

Table 84. Neiss Labs Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. Neiss Labs Erythropoietin Biosimilar Product Offerings

Table 86. Neiss Labs Recent Development

Table 87. Micro Labs Company Information

Table 88. Micro Labs Introduction and Business Overview

Table 89. Micro Labs Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. Micro Labs Erythropoietin Biosimilar Product Offerings

Table 91. Micro Labs Recent Development

Table 92. Zuventus Healthcare Company Information

Table 93. Zuventus Healthcare Introduction and Business Overview

Table 94. Zuventus Healthcare Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Zuventus Healthcare Erythropoietin Biosimilar Product Offerings

Table 96. Zuventus Healthcare Recent Development

Table 97. RPG Life Sciences Company Information

Table 98. RPG Life Sciences Introduction and Business Overview

Table 99. RPG Life Sciences Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 100. RPG Life Sciences Erythropoietin Biosimilar Product Offerings

Table 101. RPG Life Sciences Recent Development

Table 102. Unilab Company Information

Table 103. Unilab Introduction and Business Overview

Table 104. Unilab Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 105. Unilab Erythropoietin Biosimilar Product Offerings

Table 106. Unilab Recent Development

Table 107. Incepta Pharmaceuticals Company Information

Table 108. Incepta Pharmaceuticals Introduction and Business Overview

Table 109. Incepta Pharmaceuticals Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 110. Incepta Pharmaceuticals Erythropoietin Biosimilar Product Offerings

Table 111. Incepta Pharmaceuticals Recent Development

Table 112. Genius Biotherapeutics Company Information

Table 113. Genius Biotherapeutics Introduction and Business Overview

Table 114. Genius Biotherapeutics Erythropoietin Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 115. Genius Biotherapeutics Erythropoietin Biosimilar Product Offerings

Table 116. Genius Biotherapeutics Recent Development

Table 117. Key Raw Materials Lists

Table 118. Raw Materials Key Suppliers Lists

Table 119. Erythropoietin Biosimilar Downstream Customers

Table 120. Erythropoietin Biosimilar Distributors List

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

List of Figures

Figure 1. Erythropoietin Biosimilar Product Picture

Figure 2. Global Erythropoietin Biosimilar Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Erythropoietin Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Erythropoietin Biosimilar Sales Volume (2019-2030) & (K Units)

Figure 5. Global Erythropoietin Biosimilar Sales Price (2019-2030) & (US$/Unit)

Figure 6. Erythropoietin Biosimilar Report Years Considered

Figure 7. Global Erythropoietin Biosimilar Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Erythropoietin Biosimilar Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Erythropoietin Biosimilar Revenue in 2023

Figure 10. Erythropoietin Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Hospital Pharmacy Picture

Figure 12. Retail Pharmacy Picture

Figure 13. Online Pharmacy Picture

Figure 14. Global Erythropoietin Biosimilar Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 15. Global Erythropoietin Biosimilar Sales Value Market Share by Type, 2023 & 2030

Figure 16. Global Erythropoietin Biosimilar Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 17. Global Erythropoietin Biosimilar Sales Volume Market Share by Type, 2023 & 2030

Figure 18. Global Erythropoietin Biosimilar Price by Type (2019-2030) & (US$/Unit)

Figure 19. Product Picture of Hematology

Figure 20. Product Picture of Kidney Disorder

Figure 21. Product Picture of Cancer

Figure 22. Product Picture of Others

Figure 23. Global Erythropoietin Biosimilar Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 24. Global Erythropoietin Biosimilar Sales Value Market Share by Application, 2023 & 2030

Figure 25. Global Erythropoietin Biosimilar Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 26. Global Erythropoietin Biosimilar Sales Volume Market Share by Application, 2023 & 2030

Figure 27. Global Erythropoietin Biosimilar Price by Application (2019-2030) & (US$/Unit)

Figure 28. North America Erythropoietin Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 29. North America Erythropoietin Biosimilar Sales Value by Country (%), 2023 VS 2030

Figure 30. Europe Erythropoietin Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 31. Europe Erythropoietin Biosimilar Sales Value by Country (%), 2023 VS 2030

Figure 32. Asia Pacific Erythropoietin Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Erythropoietin Biosimilar Sales Value by Country (%), 2023 VS 2030

Figure 34. South America Erythropoietin Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 35. South America Erythropoietin Biosimilar Sales Value by Country (%), 2023 VS 2030

Figure 36. Middle East & Africa Erythropoietin Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 37. Middle East & Africa Erythropoietin Biosimilar Sales Value by Country (%), 2023 VS 2030

Figure 38. Key Countries/Regions Erythropoietin Biosimilar Sales Value (%), (2019-2030)

Figure 39. Key Countries/Regions Erythropoietin Biosimilar Sales Volume (%), (2019-2030)

Figure 40. United States Erythropoietin Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 41. United States Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 42. United States Erythropoietin Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 43. Europe Erythropoietin Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 44. Europe Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 45. Europe Erythropoietin Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 46. China Erythropoietin Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 47. China Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 48. China Erythropoietin Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 49. Japan Erythropoietin Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 50. Japan Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 51. Japan Erythropoietin Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 52. South Korea Erythropoietin Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 53. South Korea Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 54. South Korea Erythropoietin Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 55. Southeast Asia Erythropoietin Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 56. Southeast Asia Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 57. Southeast Asia Erythropoietin Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 58. India Erythropoietin Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 59. India Erythropoietin Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 60. India Erythropoietin Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 61. Erythropoietin Biosimilar Industrial Chain

Figure 62. Erythropoietin Biosimilar Manufacturing Cost Structure

Figure 63. Channels of Distribution (Direct Sales, and Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions